Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Evaluating the effectiveness and safety of TAS-102 plus Yttrium-90 radioembolization for the treatment of patients with colorectal cancer liver metastasis.

Posted by Medivizor on Oct 22, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of TAS-102 (Lonsurf; trifluridine-tipiracil) plus Yttrium-90 (Y-90) radioembolization (RE) for patients with colorectal cancer liver metastasis (CRLM) who are unresponsive to chemotherapy. The data showed that TAS-102 plus RE was safe and effective in these patients. Some background...

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Posted by Medivizor on Aug 27, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of panitumumab (Vectibix) rechallenge when added to maintenance therapy with FOLFIRI {fluorouracil (FU; Adrucil), folinic acid (FA; Leucovorin), irinotecan (Camptosar)} in patients with RAS wild-type metastatic colorectal cancer (mCRC). The data showed that maintenance therapy with...

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

$Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Aug 27, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of daratumumab (D; Darzalex) plus bortezomib (V; Velcade) and dexamethasone (d; Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. Some...

Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.

$Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.$

Posted by Medivizor on Jun 11, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness of decitabine (Dacogen) combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of patients with recurrent and refractory (r/r) acute myeloid leukemia (AML). The data showed that decitabine combined with allo-HSCT reduced the risk of recurrence and improved...

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Posted by Medivizor on Apr 23, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...

Evaluating the effectiveness and safety of replacing lenalidomide with pomalidomide for the treatment of patients with multiple myeloma who are unresponsive to a lenalidomide-containing combination regimen.

Posted by Medivizor on Feb 5, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of replacing lenalidomide (Revlimid) with pomalidomide (Pomalyst) for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) who were unresponsive to a lenalidomide-containing combination regimen. The data showed that pomalidomide was a safe and effective...

Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.

$Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.$

Posted by Medivizor on Jan 8, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the tolerability and effectiveness of combined therapy using venetoclax (Venclexta) and gilteritinib (Xospata) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with the FLT3 (FMS-related tyrosine kinase 3) mutation. The data showed that a combination of venetoclax and gilteritinib potentially...

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by Medivizor on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Posted by Medivizor on Oct 25, 2022 in Melanoma | 0 comments

In a nutshell The study evaluated the safety and effectiveness of tebentafusp (Kimmtrak) in patients with metastatic uveal melanoma who had received previous treatments. The study found that tebentafusp had promising effectiveness and a good safety profile in these patients. Some background Uveal melanoma is a rare and aggressive eye tumor....

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

$Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia$

Posted by Medivizor on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to compare salvage intensive chemotherapy (IC) and a venetoclax (Venclexta; VEN)-combined low-intensity regimen in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML). This study concluded that the VEN-combined regimen provided similar responses and survival rates when compared to...

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Posted by Medivizor on Sep 18, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ponatinib (Iclusig) in patients with chronic myeloid leukemia (CML) who were resistant or intolerant to previous tyrosine kinase inhibitors (TKIs). This study concluded that ponatinib was effective in heavily pretreated patients when administered in any phase of...

Evaluating the effectiveness of daratumumab-containing regimens in patients with multiple myeloma who are unresponsive to lenalidomide maintenance therapy.

Posted by Medivizor on Sep 11, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of daratumumab (Darzalex)-containing regimens in patients with multiple myeloma (MM) unresponsive to lenalidomide (Revlimid) maintenance therapy. The data showed that daratumumab-containing therapies are effective regimens in these patients. Some background Multiple myeloma (MM) is a type...

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Evaluating the effectiveness and safety of TAS-102 plus Yttrium-90 radioembolization for the treatment of patients with colorectal cancer liver metastasis.

Evaluating the effectiveness and safety of maintenance therapy with panitumumab plus FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.

Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Evaluating the effectiveness and safety of replacing lenalidomide with pomalidomide for the treatment of patients with multiple myeloma who are unresponsive to a lenalidomide-containing combination regimen.

Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the safety and effectiveness of tebentafusp in previously treated patients with advanced uveal melanoma

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Evaluating ponatinib treatment in any phase of treatment in patients with chronic myeloid leukemia resistant or intolerant to other tyrosine kinase inhibitors

Evaluating the effectiveness of daratumumab-containing regimens in patients with multiple myeloma who are unresponsive to lenalidomide maintenance therapy.

Categories

Recent Posts

Archives

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email